Market Research Logo

Cytomegalovirus (CMV) Infections - Epidemiology Forecast to 2027

DelveInsight’s ‘Cytomegalovirus (CMV) Infections - Epidemiology Forecast to 2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Cytomegalovirus (CMV) Infections in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Cytomegalovirus (CMV) Infections
The Cytomegalovirus (CMV) Infections epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Cytomegalovirus (CMV) Infections are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Cytomegalovirus (CMV) Infections Segmentation
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Sero Prevalence of Cytomegalovirus Infection in 7MM, Total Diagnosed CMV Patients in 7MM, Infants at High Risk of CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of Refractory CMV Patients after HSCT, Number of CMV Patients among Solid Organ Transplants (SOT), CMV Retinitis among HIV Patients) scenario of Cytomegalovirus (CMV) Infections in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
According to DelveInsight, the total sero-prevalent cases of Cytomegalovirus (CMV) Infections was found to be 162,856,267 in 2016 in the US.

Report Scope
• The report covers detailed overview of Cytomegalovirus (CMV) Infections explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Cytomegalovirus (CMV) Infections in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by (Total Sero Prevalence of Cytomegalovirus Infection in 7MM,Total Diagnosed CMV Patients in 7MM, Infants at High Risk of CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of Refractory CMV Patients after HSCT, Number of CMV Patients among Solid Organ Transplants (SOT),CMV Retinitis among HIV Patients)in 7MM

Key strengths
• 10 Year Forecast of Cytomegalovirus (CMV) Infections
• 7MM Coverage
• Total Sero Prevalence of Cytomegalovirus Infection ,Total Diagnosed CMV Patients in 7MM
• Prevalent Cases according to segmentation: Infants at High Risk of CMV, CMV Patients among Hematopoietic Stem Cell Transplants (HSCT), Number of Refractory CMV Patients after HSCT, Number of CMV Patients among Solid Organ Transplants (SOT),CMV Retinitis among HIV Patients

Key assessments
• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population


1. Key Insights
2. Disease Overview: Cytomegalovirus (CMV) Infections (TSC)
2.1. Introduction
2.2. Clinical Manifestations of Cytomegalovirus (CMV) Infections
2.3. Etiology
2.4. Risk Factors
2.5. Inheritance Pattern
2.6. Signs and Symptoms
2.7. Pathophysiology
2.7.1. Cytomegalovirus (CMV) Infections (TSC) Genotype Analysis
2.8. Diagnosis
2.8.1. Differential Diagnosis
2.8.2. Diagnostic Criteria
2.8.3. Diagnostic Recommendations
3. Epidemiology and Patient Population
3.1. Key Findings
3.2. Population and Forecast Parameters
4. 7MM Total Prevalent Patient Population of Cytomegalovirus (CMV) Infections
5. Country Wise-Epidemiology of Cytomegalovirus (CMV) Infections
5.1. United States
5.1.1. Prevalent Population of Cytomegalovirus (CMV) Infections in the United States
5.1.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.1.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
5.2. Germany
5.2.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Germany
5.2.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.2.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
5.3. France
5.3.1. Prevalent Population of Cytomegalovirus (CMV) Infections in France
5.3.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.3.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
5.4. Italy
5.4.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Italy
5.4.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.4.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
5.5. Spain
5.5.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Spain
5.5.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.5.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
5.6. United Kingdom
5.6.1. Prevalent Population of Cytomegalovirus (CMV) Infections in the UK
5.6.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.6.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
5.7. Japan
5.7.1. Prevalent Population of Cytomegalovirus (CMV) Infections in Japan
5.7.2. Familiar Prevalent Cases of Cytomegalovirus (CMV) Infections
5.7.3. De novo mutations Prevalent Cases of Cytomegalovirus (CMV) Infections
6. Appendix
6.1. Report Methodology
7. DelveInsight Capabilities
8. Disclaimer
9. About DelveInsight
List of Tables and Figures
Table 1: Total Sero-Prevalence of Cytomegalovirus Infection in 7MM (2016-2027)
Table 2: Total Diagnosed CMV Patients in 7MM (2016-2027)
Table 3: Total CMV Patients in the US (2016-2027)
Table 4: Infants at High Risk of CMV in the US (2016-2027)
Table 5: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2016-2027)
Table 6: Number of Refractory CMV Patients after HSCT in the US (2016-2027)
Table 7: Number of CMV Patients among SOT in the US (2016-2027)
Table 8: CMV Retinitis among HIV Patients in the US (2016-2027)
Table 9: Total CMV Patients in Germany (2016-2027)
Table 10: Number of Infants born with Congenital CMV in Germany (2016-2027)
Table 11: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany (2016-2027)
Table 12: Number of Refractory CMV Patients after HSCT in Germany (2016-2027)
Table 13: Number of CMV Patients among SOT in Germany (2016-2027)
Table 14: Total CMV Patients in France (2016-2027)
Table 15: Number of Infants born with Congenital CMV in France (2016-2027)
Table 16: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2016-2027)
Table 17: Number of Refractory CMV Patients after HSCT in France (2016-2027)
Table 18: Number of CMV Patients among SOT in France (2016-2027)
Table 19: CMV Retinitis among HIV Patients in France (2016-2027)
Table 20: Total CMV Patients in Italy (2016-2027)
Table 21: Number of Infants born with Congenital CMV in Italy (2016-2027)
Table 22: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2016-2027)
Table 23: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2016-2027)
Table 24: Number of CMV Patients among SOT in Italy (2016-2027)
Table 25: CMV Retinitis among HIV Patients in Italy (2016-2027)
Table 26: Total CMV Patients in Spain (2016-2027)
Table 27: Number of Infants born with Congenital CMV in Spain 2016-2027)
Table 28: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2016-2027)
Table 29: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2016-2027)
Table 30: Number of CMV Patients among SOT in Spain (2016-2027)
Table 31: HIV Patients at High Risk of CMV in Spain (2016-2027)
Table 32: Total CMV Patients in the UK (2016-2027)
Table 33: Number of Infants born with Congenital CMV in the UK (2016-2027)
Table 34: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2016-2027)
Table 35 Number of Refractory CMV Patients after HSCT in the UK (2016-2027)
Table 36: Number of CMV Patients among SOT in the UK (2016-2027)
Table 37: CMV Retinitis among HIV Patients in the UK (2016-2027)
Table 38: Total CMV Patients in Japan (2016-2027)
Table 39: Number of Infants born with Congenital CMV in Japan (2016-2027)
Table 40: CMV Patients among HSCT Patients in Japan (2016-2027)
Table 41: Number of Refractory CMV Patients after HSCT in Japan (2016-2027)
Table 42: Number of CMV Patients among SOT in Japan (2016-2027)
Table 43: CMV Retinitis among HIV Patients in Japan (2016-2027)
Figure 1: Classification of CMV
Figure 2: Risk Factors CMV infection
Figure 3: Mechanisms used by Human cytomegalovirus to interfere with cell-mediated immunity
Figure 4: Impact of the immune system on CMV
Figure 5: CMV Disease Mechanisms
Figure 6: Total Sero Prevalence of Cytomegalovirus Infection in 7MM (2016-2027)
Figure 7: Total Diagnosed CMV Patients in 7MM (2016-2027)
Figure 8: Total CMV Patients in the US (2016-2027)
Figure 9: Infants at High Risk of CMV in the US (2016-2027)
Figure 10: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the US (2016-2027)
Figure 11: Number of Refractory CMV Patients after HSCT in the US (2016-2027)
Figure 12: Number of CMV Patients among SOT in the US (2016-2027)
Figure 13: CMV Retinitis among HIV Patients in the US (2016-2027)
Figure 14: Total CMV Patients in Germany (2016-2027)
Figure 15: Number of Infants born with Congenital CMV in Germany (2016-2027)
Figure 16: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Germany (2016-2027)
Figure 17: Number of Refractory CMV Patients after HSCT in Germany (2016-2027)
Figure 18: Number of CMV Patients among SOT in Germany (2016-2027)
Figure 19: CMV Retinitis among HIV Patients in Germany (2016-2027)
Figure 20: CMV Retinitis among HIV Patients in Germany (2016-2027)
Figure 21: Total CMV Patients in France (2016-2027)
Figure 22: Number of Infants born with Congenital CMV in France (2016-2027)
Figure 23: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in France (2016-2027)
Figure 24:Number of Refractory CMV Patients after HSCT in France (2016-2027)
Figure 25: Number of CMV Patients among SOT in France (2016-2027)
Figure 26: CMV Retinitis among HIV Patients in France (2016-2027)
Figure 27: Total CMV Patients in Italy (2016-2027)
Figure 28: Number of Infants born with Congenital CMV in Italy (2016-2027)
Figure 29: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Italy (2016-2027)
Figure 30: Number of Refractory CMV Patients after HSCT in Italy (2016-2027)
Figure 31: Number of CMV Patients among SOT in Italy (2016-2027)
Figure 32: CMV Retinitis among HIV Patients in Italy (2016-2027)
Figure 33: Total CMV Patients in Spain (2016-2027)
Figure 34: Number of Infants born with Congenital CMV in Spain (2016-2027)
Figure 35: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in Spain (2016-2027)
Figure 36: Number of Refractory CMV Patients after HSCT in Spain (2016-2027)
Figure 37: Number of CMV Patients among SOT in Spain (2016-2027)
Figure 38: HIV Patients at High Risk of CMV in Spain (2016-2027)
Figure 39: Total CMV Patients in the UK (2016-2027)
Figure 40: Number of Infants born with Congenital CMV in the UK (2016-2027)
Figure 41: CMV Patients among Hematopoietic Stem Cell Transplants (HSCT) in the UK (2016-2027)
Figure 42: Number of Refractory CMV Patients after HSCT in the UK (2016-2027)
Figure 43: Number of CMV Patients among SOT in the UK (2016-2027)
Figure 44: CMV Retinitis among HIV Patients in the UK (2016-2027)
Figure 45: Total CMV Patients in Japan (2016-2027)
Figure 46: Number of Infants born with Congenital CMV in Japan (2016-2027)
Figure 47: CMV Patients among HSCT in Japan (2016-2027)
Figure 48: Number of Refractory CMV Patients after HSCT in Japan (2016-2027)
Figure 49: Number of CMV Patients among SOT in Japan (2016-2027)
Figure 50: CMV Retinitis among HIV Patients in Japan (2016-2027)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report